Adagrasib in advanced/metastatic NSCLC with KRAS G12C mutation

Bookmark and Share
Published: 4 Nov 2020
Views: 371
Dr Pasi Janne - Dana Farber Cancer Institute, Boston, USA

Dr Passi Janne speaks to ecancer about the activity and safety of adagrasib (MRTX849) in advanced/metastatic non–small-cell lung cancer (NSCLC) harbouring KRAS G12C mutation at the 2020 ENA virtual congress.

In this interview he explains the rationale behind using adagrasib for this type of lung cancer and then talks about what end-points were evaluated in this trial.

He goes on to explain the methodology and results of this study and says that this drug is a great break through in trying to target the KRAS pathway which for 30 years researchers have been trying to target.

Dr Janne says this is an important addition to the world of targeted therapies and winds it up by speaking how adagrasib can change the way NSCLC which is KRAS G12C positive can be treated.